In Office Genetic Testing
We are the pioneers in diagnostic testing for breast and other hereditary cancers. Today, the 35-gene Myriad myRisk® Hereditary Cancer test is keeping us at the forefront of scientific innovation in molecular diagnostics.
Recent evidence suggests up to 15% of breast cancers may be associated with a genetic predisposition. By screening for genes such as BRCA1 and BRCA2 we can determine if an individual may have a significantly increased chance to develop cancer in the future. Individuals who carry a mutation in either the BRCA1 or BRCA2 gene have a condition called Hereditary Breast and Ovarian Cancer (HBOC) syndrome, which is associated with an 87 percent risk of developing breast cancer by age 70. Mutation carriers who have already been diagnosed with cancer also have a significantly increased risk of developing a second cancer. By offering Myriad’s MyRisk genetic test we can identify patients with who have mutations in BRCA1, BRCA2, and many other genes.